MIR-34b targets HSF1 to suppress cell survival in acute Myeloid Leukemia

Oncology Research

Volumn 24, Issue 2, 2016, Pages 109-116

  Li, Gangcan ^a   Song, Yanping ^a   Zhang, Yunjie ^a   Wang, Hao ^a   Xie, Jia ^a  

^a Xi'an Central Hospital   (China)

Author keywords

Acute myeloid leukemia (AML); Heat shock transcription factor 1 (HSF1); MIR 34b; Wnt pathway

Indexed keywords

BETA CATENIN; CD11B ANTIGEN; CD14 ANTIGEN; HEAT SHOCK TRANSCRIPTION FACTOR 1; MICRORNA; MICRORNA 34B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WNT PROTEIN; DNA BINDING PROTEIN; HEAT SHOCK TRANSCRIPTION FACTOR; HSF1 PROTEIN, HUMAN; MIRN34 MICRORNA, HUMAN; TRANSCRIPTION FACTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; WNT SIGNALING PATHWAY; 3' UNTRANSLATED REGION; ACUTE MYELOID LEUKEMIA; BINDING SITE; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; RNA INTERFERENCE; TUMOR CELL LINE; WNT SIGNALING;

3' UNTRANSLATED REGIONS; ADULT; APOPTOSIS; BINDING SITES; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HEAT SHOCK TRANSCRIPTION FACTORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICRORNAS; MIDDLE AGED; RNA INTERFERENCE; TRANSCRIPTION FACTORS; WNT SIGNALING PATHWAY;

EID: 84978910867     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504016X14611963142254     Document Type: Article

References (24)

1. Lu, F.; Zhang, J.; Ji, M.; Li, P.; Du, Y.; Wang, H., Zang, S., Ma, D., Sun, X., Ji, C. miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1. Int. J. Oncol. 45:383-392; 2014.
2. Sengsayadeth, S.; Savani, B. N.; Blaise, D.; Malard, F.; Nagler, A.; Mohty, M. Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - A review from the Acute Leukemia Working Party of the EBMT. Haematology 100:859-869; 2015.
3. Ossenkoppele, G. J.; Janssen, J. J.; van de Loosdrecht, A. A. Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia. Haematology 101:20-25; 2016.
4. Xu, Y.; Cao, C.; Gong, X.; Rong, L. Inhibition of ERK5 enhances cytarabine-induced apoptosis in acute myeloid leukemia cells. Int. J. Clin. Exp. Med. 8:6446-6455; 2015.
5. Kadia, T. M.; Ravandi, F.; Cortes, J.; Kantarjian, H. New drugs in acute myeloid leukemia. Ann. Oncol. 27(5):770-778; 2016.
6. Heuston, E. F.; Lemon, K. T.; Arceci, R. J. The beginning of the road for non-coding RNAs in normal hematopoiesis and hematologic malignancies. Front. Genet. 2:94; 2011.
7. Volinia, S.; Galasso, M.; Costinean, S.; Tagliavini, L.; Gamberoni, G.; Drusco, A.; Marchesini, J.; Mascellani, N.; Sana, M. E.; Abu Jarour, R.; Desponts, C.; Teitell, M.; Baffa, R.; Aqeilan, R.; Iorio, M. V.; Taccioli, C.; Garzon, R.; Di Leva, G.; Fabbri, M.; Catozzi, M.; Previati, M.; Ambs, S.; Palumbo, T.; Garofalo, M.; Veronese, A.; Bottoni, A.; Gasparini, P.; Harris, C. C.; Visone, R.; Pekarsky, Y.; de la Chapelle, A.; Bloomston, M.; Dillhoff, M.; Rassenti, L. Z.; Kipps, T. J.; Huebner, K.; Pichiorri, F.; Lenze, D.; Cairo, S.; Buendia, M. A.; Pineau, P.; Dejean, A.; Zanesi, N.; Rossi, S.; Calin, G. A.; Liu, C. G.; Palatini, J.; Negrini, M.; Vecchione, A.; Rosenberg, A.; Croce, C. M. Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 20:589-599; 2010.
8. Spizzo, R.; Nicoloso, M. S.; Croce, C. M.; Calin, G. A. SnapShot: MicroRNAs in cancer. Cell 137(3):586; 2009.
9. Shahjahani, M.; Khodadi, E.; Seghatoleslami, M.; Asl, J. M.; Golchin, N.; Zaieri, Z. D.; Saki, N. Rare cytogenetic abnormalities and alteration of microRNAs in acute myeloid leukemia and response to therapy. Oncol. Rev. 9:261; 2015.
10. Bagchi, A.; Mills, A. A. The quest for the 1p36 tumor suppressor. Cancer Res. 68:2551-2556; 2008.
11. Rucker, F. G.; Russ, A. C.; Cocciardi, S.; Kett, H.; Schlenk, R. F.; Botzenhardt, U.; Langer, C.; Krauter, J.; Fröhling, S.; Schlegelberger, B.; Ganser, A.; Lichter, P.; Zenz, T.; Döhner, H.; Döhner, K.; Bullinger, L. Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance. Leukemia 27:353-361; 2013.
12. Pigazzi, M.; Manara, E.; Baron, E.; Basso, G. miR-34b targets cyclic AMP-responsive element binding protein in acute myeloid leukemia. Cancer Res. 69:2471-2478; 2009.
13. Newman, B.; Liu, Y.; Lee, H. F.; Sun, D.; Wang, Y. HSP90 inhibitor 17-AAG selectively eradicates lymphoma stem cells. Cancer Res. 72:4551-4561; 2012.
14. Deneberg, S.; Kanduri, M.; Ali, D.; Bengtzen, S.; Karimi, M.; Qu, Y.; Kimby, E.; Mansouri, L.; Rosenquist, R.; Lennartsson, A.; Lehmann, S. microRNA-34b/c on chromosome 11q23 is aberrantly methylated in chronic lym-phocytic leukemia. Epigenetics 9:910-917; 2014.
15. Ng, H. Y.; Wan, T. S.; So, C. C.; Chim, C. S. Epigenetic inactivation of DAPK1, p14ARF, mir-34a and -34b/c in acute promyelocytic leukaemia. J. Clin. Pathol. 67:626-631; 2014.
16. Wang, L. Q.; Kwong, Y. L.; Wong, K. F.; Kho, C. S.; Jin, D. Y.; Tse, E.; Rosèn, A.; Chim, C. S. Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia. J. Translat. Med. 12:52; 2014.
17. Majid, S.; Dar, A. A.; Saini, S.; Shahryari, V.; Arora, S.; Zaman, M. S.; Chang, I.; Yamamura, S.; Tanaka, Y.; Chiyomaru, T.; Deng, G.; Dahiya, R. miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin. Cancer Res. 19:73-84; 2013.
18. Hiroki, E.; Suzuki, F.; Akahira, J.; Nagase, S.; Ito, K.; Sugawara, J.; Miki, Y.; Suzuki, T.; Sasano, H.; Yaegashi, N. MicroRNA-34b functions as a potential tumor suppressor in endometrial serous adenocarcinoma. Int. J. Cancer 131:E395-404; 2012.
19. Fanelli, M. A.; Montt-Guevara, M.; Diblasi, A. M.; Gago, F. E.; Tello, O.; Cuello-Carrion, F. D.; Callegari, E.; Bausero, M. A.; Ciocca, D. R. P-cadherin and beta-catenin are useful prognostic markers in breast cancer patients; beta-catenin interacts with heat shock protein Hsp27. Cell Stress Chaperones 13:207-220; 2008.
20. Liao, Y.; Xue, Y.; Zhang, L.; Feng, X.; Liu, W.; Zhang, G. Higher heat shock factor 1 expression in tumor stroma predicts poor prognosis in esophageal squamous cell carcinoma patients. J. Transl. Med. 13:338; 2015.
21. Harada, M.; Benito, J.; Yamamoto, S.; Kaur, S.; Arslan, D.; Ramirez, S.; Jacamo, R.; Platanias, L.; Matsushita, H.; Fujimura, T.; Kazuno, S.; Kojima, K.; Tabe, Y.; Konopleva, M. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression. Oncotarget 6:37930-37947; 2015.
22. Ganguly, S.; Home, T.; Yacoub, A.; Kambhampati, S.; Shi, H.; Dandawate, P.; Padhye, S.; Saluja, A. K.; McGuirk, J.; Rao, R. Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia. Oncotarget 6:31767-31779; 2015.
23. Fiskus, W.; Sharma, S.; Saha, S.; Shah, B.; Devaraj, S. G.; Sun, B.; Horrigan, S.; Leveque, C.; Zu, Y.; Iyer, S.; Bhalla, K. N. Pre-clinical efficacy of combined therapy with novel beta-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia 29:1267-1278; 2015.
24. Chou, S. D.; Murshid, A.; Eguchi, T.; Gong, J.; Calderwood, S. K. HSF1 regulation of beta-catenin in mammary cancer cells through control of HuR/elavL1 expression. Oncogene 34:2178-2188; 2015.